Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
19247 | 449 | 46.5 | 92% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
3737 | 720 | PIM 2//TRANSLATIONALLY CONTROLLED TUMOR PROTEIN//TCTP |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | PIM 2 | Author keyword | 68 | 100% | 5% | 22 |
2 | PIM 1 | Author keyword | 40 | 51% | 12% | 56 |
3 | PIM 3 | Author keyword | 35 | 89% | 4% | 16 |
4 | PIM KINASES | Author keyword | 25 | 73% | 4% | 19 |
5 | PIM KINASE | Author keyword | 21 | 75% | 3% | 15 |
6 | PIM1 KINASE | Author keyword | 18 | 89% | 2% | 8 |
7 | PIM 1 KINASE | Author keyword | 13 | 69% | 2% | 11 |
8 | PIM1 | Author keyword | 8 | 45% | 3% | 14 |
9 | PIM INHIBITORS | Author keyword | 6 | 80% | 1% | 4 |
10 | CANC MICROENVIRONM PROGRAM | Address | 6 | 71% | 1% | 5 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PIM 2 | 68 | 100% | 5% | 22 | Search PIM+2 | Search PIM+2 |
2 | PIM 1 | 40 | 51% | 12% | 56 | Search PIM+1 | Search PIM+1 |
3 | PIM 3 | 35 | 89% | 4% | 16 | Search PIM+3 | Search PIM+3 |
4 | PIM KINASES | 25 | 73% | 4% | 19 | Search PIM+KINASES | Search PIM+KINASES |
5 | PIM KINASE | 21 | 75% | 3% | 15 | Search PIM+KINASE | Search PIM+KINASE |
6 | PIM1 KINASE | 18 | 89% | 2% | 8 | Search PIM1+KINASE | Search PIM1+KINASE |
7 | PIM 1 KINASE | 13 | 69% | 2% | 11 | Search PIM+1+KINASE | Search PIM+1+KINASE |
8 | PIM1 | 8 | 45% | 3% | 14 | Search PIM1 | Search PIM1 |
9 | PIM INHIBITORS | 6 | 80% | 1% | 4 | Search PIM+INHIBITORS | Search PIM+INHIBITORS |
10 | PIM KINASE INHIBITION | 6 | 100% | 1% | 4 | Search PIM+KINASE+INHIBITION | Search PIM+KINASE+INHIBITION |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BAD MEDIATED APOPTOSIS | 90 | 87% | 10% | 45 |
2 | PROTOONCOGENE PIM 1 | 53 | 95% | 4% | 18 |
3 | PHOSPHORYLATES BAD | 44 | 88% | 5% | 21 |
4 | SERINE THREONINE KINASE ACTIVITY | 19 | 76% | 3% | 13 |
5 | SERINE THREONINE KINASE PIM 1 | 17 | 70% | 3% | 14 |
6 | E MU MYC | 15 | 39% | 7% | 31 |
7 | LYMPHOMAGENESIS | 9 | 24% | 8% | 34 |
8 | PROVIRAL INSERTION SITE | 8 | 75% | 1% | 6 |
9 | PUTATIVE ONCOGENE PIM 1 | 8 | 52% | 2% | 11 |
10 | SERINE THREONINE KINASE PIM 2 | 7 | 64% | 2% | 7 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
PIM kinase (and Akt) biology and signaling in tumors | 2015 | 1 | 111 | 65% |
The PIM Family of Serine/Threonine Kinases in Cancer | 2014 | 15 | 154 | 80% |
Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities | 2013 | 27 | 140 | 83% |
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers | 2010 | 107 | 139 | 74% |
For better or for worse: the role of Pim oncogenes in tumorigenesis | 2011 | 119 | 168 | 59% |
Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update | 2014 | 5 | 37 | 97% |
PIM1 kinase as a target for cancer therapy | 2012 | 28 | 118 | 68% |
The PIM kinases in hematological cancers | 2012 | 21 | 156 | 65% |
Pim kinase inhibitors: a survey of the patent literature | 2010 | 35 | 61 | 61% |
Why target PIM1 for cancer diagnosis and treatment? | 2010 | 31 | 155 | 61% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CANC MICROENVIRONM PROGRAM | 6 | 71% | 1.1% | 5 |
2 | MOL BIOREGULAT | 1 | 10% | 2.9% | 13 |
3 | PANCREAS HEPATOBILIARY | 1 | 100% | 0.4% | 2 |
4 | THER EUT PROT DISCOVERY | 1 | 100% | 0.4% | 2 |
5 | ABO AKAD UNIV | 1 | 18% | 1.6% | 7 |
6 | SAN DIEGO STATE HEART | 1 | 29% | 0.9% | 4 |
7 | EXPT THER EUT PROGRAMME | 1 | 11% | 1.6% | 7 |
8 | CANC SHANGHAI CANC | 1 | 33% | 0.4% | 2 |
9 | BURNET INCORPORATING | 1 | 50% | 0.2% | 1 |
10 | HLTH DISPARTIES MOL MED | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000129667 | GFI1B//GFI1//ZELLBIOL TUMORFOR |
2 | 0.0000058899 | TPL2//TPL 2//TPL2 KINASE |
3 | 0.0000056013 | NKX31//LOBUND//3 2 DIMETHYL 4 AMINOBIPHENYL |
4 | 0.0000052158 | ASTROCYTE ELEVATED GENE 1//AEG 1//METADHERIN |
5 | 0.0000050756 | PERSISTENT VIRAL DIS//FRIEND VIRUS//MOMULV TS1 |
6 | 0.0000045226 | DEK//ACUTE BASOPHILIC LEUKEMIA//DEK CAN |
7 | 0.0000044941 | UNIT IMMUNOMICROBIO ENVIRONM CARCINOGENESIS//ANTI INTERLEUKIN 6 ANTIBODY//AUTOCRINE AND PARACRINE LOOPS |
8 | 0.0000041107 | FLT3//FLT3 ITD//NPM1 |
9 | 0.0000032838 | MIG 6//ACK1//RALT |
10 | 0.0000032464 | MYC//MAX//C MYC |